Immune Pharmaceuticals appoints three
pharmafile | January 23, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Immune Pharmaceuticals, cameron durrant, elliot maza, gad berdugoÂ
US antibody development firm Immune Pharmaceuticals has appointed Gad Berdugo (pictured) as its executive VP and chief financial officer, and Cameron Durrant as the lead independent director and chairman of its compensation committee.
Additionally it has confirmed the appointed of Elliot Maza as an independent director and chairman of its committee. The reorganisation was in conjunction with the resignations of two directors and the appointment of Berdugo, who is leaving the board in order to become its new CFO.
Berdugo was previously a managing director and head of the global life sciences at Tegris Advisors, but started his career at Abbott and then at Baxter Healthcare, where he was director of global business development for the Bio-Pharmaceutical Group.
Durrant has worked at several big pharma companies, including most recently as worldwide vice president at Johnson & Johnson, and previously as VP at Pharmacia, prior to its acquisition by Pfizer.
Maza is currently is chairman, chief executive and CFO at Intellect Neurosciences. Previously he was the chief executive and CFO at Biozone Pharmaceuticals.
Durrant says: “I am delighted to take this responsibility at Immune. I believe that the company is at an exciting point in its evolution and has a clear strategic plan ready for execution. I believe that together with Gad Berdugo joining the team as CFO and Elliot Maza joining the board that the company is well positioned for success.”
Related Content
Lonza wins another antibody contract
Lonza has won a contract to manufacture Immune Pharmaceuticals’ antibody-based drug for inflammatory disorders, bertilimumab, …
